Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,106,900.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director James Wilson sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $110.69, for a total value of $1,106,900.00. Following the transaction, the director owned 1,064,543 shares of the company’s stock, valued at $117,834,264.67. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $110.29 on Friday. The business’s fifty day moving average price is $108.56 and its two-hundred day moving average price is $75.21. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $126.38. The stock has a market capitalization of $11.92 billion, a price-to-earnings ratio of 262.60 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The company had revenue of $256.15 million for the quarter, compared to the consensus estimate of $221.15 million. During the same quarter in the previous year, the company earned $0.29 EPS. The firm’s revenue for the quarter was up 31.7% compared to the same quarter last year. Research analysts expect that Corcept Therapeutics Incorporated will post 1.86 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. UBS Group set a $135.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, May 28th. Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Canaccord Genuity Group boosted their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. HC Wainwright restated a “buy” rating and set a $165.00 price target on shares of Corcept Therapeutics in a research report on Friday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $138.17.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for Lifyorli (relacorilant) combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The recommendation moves Corcept closer to a potential European launch, expanding the commercial opportunity for its oncology pipeline, although final approval by the European Commission is still required. Corcept receives CHMP recommendation
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $165 price target, implying substantial upside from recent trading levels. The bullish view reflects optimism about Lifyorli’s regulatory progress and Corcept’s growth potential.
• Positive Sentiment: Zacks Research raised several longer-term EPS forecasts, including its FY2027 estimate to $2.05 from $1.91 and FY2028 estimate to $4.31 from $4.07. These revisions suggest analysts see improving earnings potential as new products contribute to revenue.
• Neutral Sentiment: Reports highlighted Corcept among companies benefiting from favorable European drug recommendations, reinforcing the visibility of the Lifyorli regulatory milestone. EU drug recommendations
• Negative Sentiment: James Wilson, a Corcept director, sold 10,000 shares for approximately $1.11 million, while another insider previously sold 10,000 shares. Wilson still retains more than 1.06 million shares, limiting the significance of the transaction, but insider selling can weigh on investor sentiment.
• Negative Sentiment: Zacks’ FY2026 EPS estimate of $1.39 is below the broader full-year consensus of $2.02, indicating some concern about near-term earnings expectations despite stronger later-year forecasts.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors have recently modified their holdings of CORT. BlackRock Inc. acquired a new position in shares of Corcept Therapeutics during the second quarter worth approximately $1,080,964,000. Parallel Advisors LLC increased its holdings in shares of Corcept Therapeutics by 2.5% in the first quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock valued at $160,329,000 after purchasing an additional 96,763 shares in the last quarter. Geode Capital Management LLC raised its position in Corcept Therapeutics by 38.0% in the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after purchasing an additional 734,646 shares during the last quarter. First Trust Advisors LP lifted its holdings in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after buying an additional 1,480,059 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Corcept Therapeutics during the 2nd quarter worth $49,185,000. 93.61% of the stock is owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.